even
though
bronchiol
diseas
recogn
mani
year
still
therapeut
strategi
beyond
support
therapi
bronchiol
frequent
caus
hospit
admiss
children
less
year
age
incid
estim
case
year
worldwid
case
requir
hospit
acknowledg
virus
caus
bronchiol
studi
focu
rsv
rsv
caus
sever
form
bronchiol
children
risk
factor
includ
prematur
cardiovascular
diseas
immunodefici
virus
involv
caus
bronchiol
includ
rv
hmpv
hbov
coinfect
rv
seem
associ
less
sever
acut
diseas
correl
earli
infect
subsequ
wheez
bronchiti
asthma
later
childhood
adulthood
support
therapi
use
intraven
fluid
oxygen
supplement
administ
nasal
cannula
cpap
complic
patient
addit
pharmacolog
therapi
includ
epinephrin
hyperton
salin
corticosteroid
epinephrin
seem
greatest
shortterm
benefit
reduc
need
hospit
admiss
wherea
hyperton
salin
corticosteroid
seem
reduc
length
hospit
stay
bronchiol
preval
diseas
children
rv
seem
play
import
role
perhap
studi
center
around
rv
contribut
initi
diseas
follow
patholog
bronchiol
lead
reason
hospit
infant
younger
year
age
incid
peak
decemb
march
common
caus
bronchiol
respiratori
syncyti
viru
rsv
infect
although
children
mild
bronchiol
manifest
sever
respiratori
symptom
requir
intens
care
risk
factor
sever
bronchiol
includ
prematur
cardiovascular
diseas
chronic
pulmonari
diseas
immunodefici
bronchiol
young
infant
caus
also
respiratori
virus
rsv
one
common
rhinoviru
rv
major
caus
common
cold
often
affect
children
famili
histori
atopi
blood
eosinophilia
therapi
bronchiol
mainli
support
supplement
oxygen
nasal
wash
intraven
iv
fluid
clinic
trial
test
glucocorticoid
epinephrin
recombin
human
dnase
hyperton
salin
bronchiol
report
highli
controversi
result
bronchiol
first
acut
lower
respiratori
tract
viral
infect
affect
termin
respiratori
bronchioli
infant
less
month
age
result
bronchiol
obstruct
firsttim
bronchiol
clinic
diagnosi
base
runni
nose
sometim
accompani
fever
cough
mildtosever
respiratori
distress
diffus
rale
auscult
differ
opinion
defin
bronchiol
clinic
north
american
vs
european
make
difficult
interpret
clinic
therapeut
epidemiolog
studi
includ
wheez
infant
less
month
diagnost
criteria
north
american
definit
might
caus
overlap
bronchiol
earli
wheez
bronchiti
bronchiol
frequent
diseas
children
less
month
age
lead
caus
hospit
group
infant
mainli
children
younger
month
season
bronchiol
epidem
peak
decemb
march
year
million
new
case
bronchiol
report
worldwid
infant
affect
requir
hospit
bronchiol
viral
diseas
common
viru
involv
pathogenesi
bronchiol
one
seem
caus
sever
diseas
rsv
virus
caus
bronchiol
includ
rv
human
metapneumoviru
hmpv
human
bocaviru
hbov
enteroviru
adenoviru
influenza
viru
human
coronaviru
parainfluenza
viru
sometim
virus
manifest
coinfect
mainli
rsvhbov
rsvrv
sever
bronchiol
correl
also
viral
load
bacteri
coinfect
rare
describ
infant
bronchiol
despit
antibiot
prescript
case
bronchiol
safe
manag
home
parent
adequ
educ
recogn
clinic
sign
indic
deterior
risk
sever
bronchiol
highest
prematur
infant
age
younger
month
small
weight
male
sex
low
socioeconom
condit
matern
smoke
rsv
infect
underli
comorbid
cardiovascular
diseas
immunodefici
chronic
respiratori
diseas
bronchopulmonari
dysplasia
infant
mainli
risk
factor
need
admiss
intens
care
unit
icu
viral
respiratori
infect
caus
respiratori
epithelium
necrosi
loss
ciliat
epitheli
cell
collect
desquam
airway
epitheli
cell
lymphocyt
neutrophil
infiltr
within
termin
respiratori
bronchioli
edema
around
airway
widespread
cellular
debri
inflammatori
cell
fibrin
could
caus
airway
obstruct
develop
mucu
plug
partial
total
occlud
bronchioli
ballvalv
mechan
induc
air
trap
respiratori
tract
distal
partial
occlud
bronchioli
atelectasi
bronchioli
complet
occlud
bronchiolar
smooth
muscl
minor
role
obstruct
bronchodil
therapi
achiev
limit
benefit
acut
bronchiol
atelectasi
air
trap
caus
alter
ventilationperfus
vq
ratio
clinic
result
hypoxemia
increas
co
anatom
function
alter
increas
airway
resist
decreas
dynam
lung
complianc
increas
work
breath
caus
respiratori
distress
mani
children
reduc
fluid
intak
result
mildtosever
dehydr
metabol
acidosi
diagnosi
acut
bronchiol
support
care
medic
histori
physic
examin
bronchiol
diagnosi
requir
epidemiolog
data
age
younger
month
previou
upper
respiratori
tract
infect
runni
nose
cough
rare
fever
diffus
rale
bronchiol
dynam
diseas
character
worsen
clinic
pictur
first
h
children
respiratori
distress
tachypnea
retract
nasal
flare
low
satur
dehydr
infant
born
preterm
first
symptom
could
apnea
sever
case
bronchiol
could
complic
metabol
acidosi
inappropri
antidiuret
hormon
secret
bacteri
superinfect
current
guidelin
recommend
chest
xray
blood
test
infant
undergo
diagnost
procedur
suggest
clinic
condit
sever
present
worsen
clinic
condit
criteria
hospit
admiss
includ
respiratori
distress
apnea
respiratori
rate
greater
per
minut
oxygen
requir
dehydr
oral
liquid
intak
lower
total
hour
requir
low
famili
complianc
heart
rate
respiratori
rate
percutan
oxygen
satur
spo
monitor
first
h
hospit
discharg
criteria
decreas
respiratori
rate
evid
respiratori
distress
adequ
famili
educ
oxygen
satur
remain
stabl
n
room
air
adequ
oral
feed
infant
mild
bronchiol
gener
manag
includ
therapi
intend
reduc
work
breath
restor
clinic
stabil
case
recommend
measur
upper
airway
clearanc
nasal
suction
prone
posit
improv
diaphragmat
function
hydrat
oxygen
breast
feed
small
volum
frequent
feed
encourag
infant
clinic
condit
worsen
respiratori
rate
per
minut
oral
liquid
intak
reduc
h
sign
dehydr
treatment
includ
iv
hydrat
oxygen
administ
via
nasal
cannula
head
box
uk
supplement
oxygen
therapi
usual
administ
oxygen
satur
less
air
wherea
american
academi
pediatr
recommend
use
oxygen
satur
fall
persist
previous
healthi
infant
usa
introduct
routin
measur
oxygen
satur
led
increas
hospit
bronchiol
without
signific
chang
mortal
henc
probabl
littl
gain
administ
oxygen
infant
oxygen
satur
greater
absenc
respiratori
distress
accept
lower
oxygen
satur
threshold
administ
supplement
oxygen
might
decreas
rate
length
hospit
stay
oxygen
given
heat
humidifi
highflow
nasal
cannula
hfnc
therapi
modal
suggest
improv
toler
decreas
need
mechan
ventil
devic
deliv
oxygen
heat
humidifi
high
flow
lmin
nasal
cannula
suppli
oxygen
mixtur
contain
known
inspir
concentr
hfnc
advantag
flow
set
valu
greater
child
inspiratori
peak
adjust
minim
inhal
ambient
air
maintain
constant
fio
equal
import
high
flow
humidifi
heat
oxygen
minim
advers
effect
relat
inhal
cold
anhydr
ga
mucos
dehydr
reduc
ciliari
clearanc
increas
bronchobstruct
stimulu
final
continu
posit
airway
pressur
cpap
effect
caus
high
flow
gase
keep
airway
patent
respir
phase
effici
hfnc
depend
cannula
adhes
nostril
adequ
flow
set
accord
patient
infant
sever
respiratori
distress
po
b
mm
hg
pco
n
mm
hg
infant
apnea
cpap
indic
current
clinic
evid
show
bronchodil
albuterol
ipratropium
bromid
epinephrin
produc
small
shortterm
improv
clinic
score
trial
albuterol
justifi
recommend
patient
famili
histori
atopi
inhal
albuterol
improv
patient
clinic
statu
therapi
continu
among
bronchodil
epinephrin
appear
greatest
short
term
benefit
provid
better
shortterm
improv
clinic
score
placebo
albuterol
particularli
first
h
significantli
reduc
risk
admiss
day
effect
length
hospit
stay
benefit
relat
combin
adrenerg
properti
thu
potenti
greater
vasoconstrictor
effect
edema
reduct
nebulis
hyperton
salin
believ
improv
airway
hydrat
osmosi
caus
water
move
interstitium
airway
therebi
decreas
interstiti
edema
mucos
viscos
result
improv
mucociliari
clearanc
airway
secret
effect
reduc
hospit
stay
among
infant
nonsever
acut
viral
bronchiol
appear
efficaci
safe
combin
bronchodil
improv
clinic
sever
score
outpati
inpati
popul
current
evid
demonstr
neither
durat
hospit
sever
symptom
improv
inhal
system
corticosteroid
singl
studi
show
combin
therapi
dexamethason
epinephrin
may
significantli
reduc
hospit
admiss
compar
placebo
accord
literatur
rv
infant
receiv
oral
corticosteroid
therapi
acut
sever
viral
episod
less
like
recurr
wheez
follow
year
scarc
evid
support
use
antibiot
bronchiol
antivir
drug
benefit
acut
bronchiol
caffein
rare
use
young
expreterm
infant
bronchiol
apnea
mild
respiratori
symptom
may
last
week
bronchiol
children
discharg
parent
inform
home
care
manag
airway
clearanc
posit
feed
aerosol
therapi
mani
studi
show
infant
earli
sever
bronchiol
need
hospit
admiss
significantli
higher
risk
recurr
wheez
subsequ
asthma
later
year
correl
explain
combin
factor
relat
viral
pathogen
role
host
genet
predisposit
environment
factor
viral
role
implic
multipl
mechan
first
infect
might
caus
direct
damag
respiratori
epithelium
incomplet
develop
lung
equal
well
known
crucial
role
viral
infect
asthma
exacerb
alter
respons
virus
also
activ
specif
molecular
pathway
induc
synthesi
mani
factor
regul
remodel
alveolar
develop
vascular
endotheli
growth
factor
vegf
nitric
oxid
transform
growth
factor
tgf
amphiregulin
fibroblast
growth
factor
fgf
viral
infect
seem
also
upregul
neurotrophin
substanc
remodel
neuron
connect
thu
promot
nonspecif
bronchial
hyperrespons
bronchial
hyperrespons
might
last
could
explain
wheez
later
life
whether
viral
infect
predispos
select
individu
asthma
caus
host
immun
respons
whether
respiratori
virus
identifi
infant
alreadi
predispos
respons
asthma
develop
ampl
evid
document
cytokin
dysregul
specif
biolog
therapeut
prognost
signific
infant
bronchiol
remain
poorli
understood
cytokin
imbal
lead
interleukin
il
overexpress
il
il
il
seem
depend
host
factor
genet
predisposit
immun
system
immatur
also
environment
factor
role
environment
factor
highlight
hygien
hypothesi
increas
incid
allerg
diseas
depend
vaccin
decreas
infect
due
antibiot
use
chang
famili
model
event
impair
matur
weaken
host
immun
viral
infect
factor
join
two
hit
hypothesi
theori
bronchial
hyperrespons
asthma
develop
viral
infect
predispos
children
famili
histori
atopi
dysregul
cytokin
respons
imbal
toward
pathway
evid
recent
year
show
variou
viral
infect
caus
bronchiol
differ
risk
wheez
asthma
develop
childhood
prospect
studi
children
less
month
age
hospit
sever
rsv
bronchiol
follow
castro
et
al
show
rsv
bronchiol
risk
factor
persist
wheez
asthma
first
six
year
life
symptom
gener
persist
school
age
also
detect
increas
express
chemokin
cc
motif
ligand
chemoattract
inflammatori
cell
nasal
epithelium
children
episod
bronchiol
increas
valu
highli
predict
develop
asthma
schoolag
overexpress
bronchiol
seem
genet
determin
possibl
link
increas
sever
clinic
manifest
rsv
acut
infect
persist
wheez
followup
hereditari
suscept
lower
respiratori
tract
infect
receiv
support
goetghebu
janssen
detect
gene
relat
innat
immun
vitamin
receptor
induc
nitric
oxid
synthas
close
associ
develop
bronchiol
studi
conduct
recent
year
small
seri
infant
earli
sever
rsv
bronchiol
show
rsv
infect
import
risk
factor
develop
asthma
clinic
allergi
sensit
common
allergen
also
age
bronchiol
caus
rsv
parainfluenza
viru
influenza
viru
seem
similar
longterm
prognosi
wherea
mani
studi
suggest
children
rv
bronchiol
appear
higher
risk
develop
persist
wheez
asthma
adulthood
base
evid
group
test
nasal
aspir
infant
bronchiol
respiratori
virus
use
panel
realtim
reversetranscriptasepolymerasechainreact
rtpcr
nest
pcr
assay
panel
identifi
viru
patient
among
identifi
three
group
accord
viral
agent
observ
infant
rsv
bronchiol
younger
breastf
shorter
time
sever
bronchiol
preval
diffus
air
trap
chest
xray
convers
infant
hbov
bronchiol
oldest
breastf
longer
mild
clinic
form
patchi
infiltr
chest
xray
convers
infant
rv
bronchiol
moder
sever
bronchiol
frequent
famili
histori
atopi
higher
blood
eosinophil
count
infant
find
seem
suggest
rv
preferenti
infect
infant
predispos
asthma
other
confirm
recent
paper
evalu
recurr
wheez
two
physicianverifi
wheez
episod
oneyear
followup
infant
hospit
bronchiol
first
year
life
found
major
risk
factor
wheez
episod
acut
bronchiol
rv
infect
posit
hered
asthma
also
confirm
higher
blood
eosinophil
count
lower
blood
crp
concentr
fewer
radiologicallydocu
lung
consolid
infant
recurr
wheez
nonwheez
infant
result
receiv
support
studi
particularli
coast
childhood
origin
asthma
studi
start
investig
interact
genet
predisposit
develop
atop
diseas
viral
infect
environment
factor
cohort
newborn
high
risk
allerg
diseas
show
combin
genet
predisposit
famili
histori
atopi
rvinduc
wheez
age
three
year
associ
higher
risk
asthma
develop
age
year
studi
conduct
children
bronchiol
divid
rsv
nonrsv
etiolog
show
recurr
wheez
develop
substanti
higher
rate
children
hospit
bronchiol
caus
virus
rsv
unfortun
studi
koponen
et
al
lack
detail
nonrsv
bronchiol
rv
might
play
import
role
vitro
find
seem
confirm
rv
preferenti
affect
lower
airway
caus
bronchiol
atop
children
prone
wheez
studi
design
investig
balanc
type
type
immun
respons
rv
papadopoulo
et
al
found
peripher
blood
mononuclear
cell
pbmc
incub
rv
atop
subject
produc
wherea
pbmc
nonatop
subject
produc
defect
type
immun
respons
rv
predispos
patient
asthma
may
contribut
develop
acut
asthma
exacerb
promot
type
inflamm
diminish
viral
clearanc
defici
type
antivir
immun
respons
bronchiol
old
diseas
one
still
therapeut
strategi
longstand
evid
underlin
correl
bronchiol
wheez
bronchiti
although
rsv
remain
common
pathogen
associ
bronchiol
emerg
evid
document
rv
risk
factor
subsequ
wheez
bronchiti
precis
mechan
predispos
children
wheez
remain
controversi
answer
question
research
effort
switch
rsv
rv
